Loading clinical trials...
Loading clinical trials...
Primary objectives WP1: Evaluate the prevalence of FOF in the study population and how this varies over time. Evaluate whether there are relationships between the variables investigated (clinical, mo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Universita di Verona
NCT06839469 · Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
NCT07037862 · Duchenne Muscular Dystrophy (DMD)
NCT01568658 · Muscular Dystrophies, Muscle Myopathies, and more
NCT07099677 · Hypertension, Fall Risk, and more
NCT05724173 · Anarthria, Dysarthria, and more
Azienda Ospedaliera Universitaria Integrata Verona - UOC di Neuroriabilitazione
Verona, verona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions